Patent Application
20050176067
The present application hereby claims priority under 35 U.S.C. §119 on German patent application number DE 10 2004 005 711.7 filed Feb. 5, 2004, the entire contents of which are hereby incorporated herein by reference.
The number of allergic diseases has drastically risen over the last few years as a result of an increasing environmental impact. Thus, the demand for methods to detect this immunological dysfunction has also increased.
With the onset of an allergy, the reaction of the body's own immune system results in symptoms such as erythema, stinging eyes, swelling of the skin and/or mucosa and breathlessness right through to asthma attacks. In addition to the outwardly visible allergic reaction, considerable changes in the immune system of the body of an allergy sufferer occur. Contact with an allergen results in special types of antibodies such as immunoglobulin E (IgE) being found in the blood in higher concentrations, which are not present in healthy people without allergies.
On the basis of the specifity, in other words by way of the reaction and/or binding behaviour, the antibodies can be identified. As such, the allergen generates the formation of the IgE, each IgE only binding itself to the allergen which was responsible for its formation.
There are two different approaches used in detecting the allergen:
1. Examination of the Body's Own Outwardly Visible Reaction:
In order to diagnose an allergy in a patient, an ‘in vivo’ test is generally carried out, i.e. a test directly on the patient, the so-called ‘prick test’, whereby the patient is brought into contact with various allergy inducing agents and an allergic reaction based on the subsequent immune reaction is identified, in other words the reaction of the skin to the allergen. Various diluted allergens are injected under the skin surface (arm or back) at marked points. Finally the skin reaction of the test person is monitored over several days in respect of redness or the formation of welts and the extent of the allergic reaction is evaluated.
This method is painful for the patient and can therefore not be repeated often. Furthermore, the number of allergens which can be tested is restricted.
2. Examination of the Immune System—Immunological Tests:
The market leader in the current ‘in vitro’ allergy test, in other words the diagnostics in vitro with a serum sample from the patient, is the CAP test from the Pharmacia company. This relates to an optical readout principle. A carrier polymer, such as a CNBr-activated cellulose derivative for example allows various allergens to be adsorptively immobilised. Specific IgE present in patient serum binds itself to the position with the corresponding allergen and is detected by means of anti-human IgE. Anti-human IgE is bound to β-galactosidase or 125I. The bound IgE is detected photometrically in the case of the enzyme immunoassays, or correspondingly on the basis of the radioactive isotope decay. The disadvantage of this test is the large quantity of serum required, amounting to more than 10 ml and the high outlay in apparatus and time of more than 30 minutes.
Further immunological tests available on the market are based on the detection of a colour response to a simple cellulose test strip, such as allergoscreen from Ganzimmun or allergodip from Allergopharma. This detection method is not overly sensitive and provides a first qualitative statement about the existence of allergic diseases, but is however not suitable for clinical diagnostics. [IV].
An object of an embodiment of the invention is to provide a biosensor for detecting an allergy in a person and/or an antibody in his/her blood, by way of a biosensor and an operating procedure. As such, a plurality of allergies can preferably be detected and differentiated with a high level of sensitivity.
An object may be based on the knowledge that,
The technology of the biochip base may be known from: [I], [II], [III].
Exemplary embodiments are described below with reference to exemplary schematic drawings not restricted to the invention, in which;
Structure of a biosensor which can be read-out electronically to detect the specific immunoglobulin E (IgE), which appears as an antibody in the serum of the person with an allergy.
The biochip and/or the biochip array are characterized by the following characteristics:
The silicon chips of approximately 4.5 mm*6 mm in size which are contacted with the readout device by way of a printed circuit board each carry a plurality, particularly between 12 and 26, of circular areas with interdigital structures of a diameter of 200 μm to 400 μm, depending on their layout. The comb-like electrode finders 13 of the interdigital structures have a width of 1 μm and a gap of a maximum of 1.0 μm. In addition, a counter electrode 11 made from gold is arranged on the chip. In this case, the Ag/AgCl reference electrode 9, against which the electrode potential is set, is not found on the chip, but is integrated in the flow system.
The allergen 6 is immobilized on the gold electrode 3 of the sensor chip 10. This is done with the aid of a first coat made from protein, comprising protein A, G G′ or L, in combination with subsequent coat with an immobilised so-called captor antibody 5, to which the allergen 6 found in the third coat is bound.
In the case of an allergic disease, the allergen-specific IgE present in the serum of an allergic patient will bind itself to the allergen 6 immobilised at the surface on the biochip 10 by means of antigen/antibody coupling. This binding is detected by way of an enzyme-marked second antibody, the detection antibody 7.
The sensor signal is read out electrically at the sensor surface 1, using a multichannel potentiostat after an enzymatic release of a redox reactive molecule, p-Aminophenol for example.
The type of allergy, i.e. against which allergen the patient shows an allergic reaction can be extremely quickly, efficiently and cost-effectively determined by detecting the IgE developing in the patient serum, with the aid of an electrical biochip.
The biosensor used is silicon-based with gold interdigital structures 12 [I, II, III].
The allergen is immobilised on the gold interdigital structures of the biochip, by way of the following coat structure, see
The first step is to produce a protein base coating, which takes place by way of unspecific adsorption of protein A, G, G′ or L for example, directly onto the gold surface of the interdigital structure. The choice of protein depends on the captor antibody 5.
The second step is the explicit binding of the captor antibody 5 to the first protein base coating.
In the third step, the corresponding allergen 6 is selectively bound to the captor antibody 5, thus providing a defined and highly selective chip surface.
By immobilising different allergens at different positions on a sensor array, whereby several hundred positions are possible, the sensor surface becomes a analysis landscape which can be used with a plurality of different allergens, by way of the above described coating of the biochip (protein coating/captor antibody/allergen).
The coated biosensor chip is incubated with patient serum in order to implement the ‘in vitro’ allergy test. With a positive reaction, the allergen-specific immunoglobulin E 14 present in the serum binds itself to the corresponding allergen 6 immobilised on the chip, by way of an antigen/antibody reaction.
The biochip is bonded with a multichannel potentiostat for an electrical (amperometric) readout,
Another enzyme-linked detection antibody 7 can be used to detect the specific immunoglobulin IgE, whereby instead of p-aminophenylphosphate another ‘suitable’ substrate must develop to react with the used enzyme 8,. Further suitable enzyme-bound antibodies and/or their substrates are: B galactosidase, coupled to the detection antibody and p-aminophenyl-β-D-galactopyranoside as a substrate.
A total of three antigens/antibody couplings are used in this detection. The first is arranged between the captor antibody 5 and the allergen 6 immobilised on the biosensor, the second arranged between allergen 6 and the allergen-specific immunoglobulin E 14 and the third arranged between the allergen-specific immunoglobulin E 14 and the detection antibody.
Major benefits of embodiments of the invention include the fact that disadvantages prevailing with the conventional allergy test can be reduced or even minimized with the aid of this amperometric allergy biochip.
The outstanding features of the test principle presented are that by using correspondingly suitable sensor chips and potentiostats, a large number of allergens, for instance more than 100 can be read out in a very short space of time (10 minutes), and with a very low quantity of serum (˜1μ1).
The patient is disturbed only once in order to take one drop of blood, this being possible without an injection and thus being considerably more pleasant for the test subject, in comparison with current ‘in vitro’ allergy tests which require a blood sample of several millilitres.
The test can be repeated several times over a short period of time.
Sample preparation such as cell disruption, cleaning of the serum for instance is not necessary.
The use of an electrical biochip allows the disadvantages of optical methods to be reduced, said methods above all involving a major outlay in equipment.
An extremely cost-effective and simple allergy test can be produced using this biochip.
The multi structure of the biochip also shows no matrix effects which would otherwise lead to a more complex sample preparation thereby considerably increasing the test duration.
Relevant test setups for the invention are as follows:
a) Structure of the Measuring Station
b) Structure of the Sensor Chip System
c) Interdigital Structures
Considering as an example the household dust mite allergens, ‘Der p2’, the operability of the measurement principle introduced was tested in a practical application as an in vitro allergy test. In this test, only two positions (2×2 interdigital structures) of a chip were firstly coated in parallel and read out. The allergen was bound to the electrode surface by means of protein G′ and the monoclonal antibody 1D8 (Anti-Der p2). Finally position 1 was incubated with a blood sample which was already positively tested in another method and position 2 with a negative.
By adding the detection antibody 7 (Anti-Human IgE), in the case of the positive sample, Der p2-specific IgE 14 is marked with enzyme 8 and the chip 10 is directly read out. For this the sensor is built into the flow cell, bonded with the multichannel potentiostat and initially rinsed with buffers. After the addition of the p-aminophenylphosphate, there is a wait of around 30 seconds and then the flow is stopped, see
Since the p-aminophenol generated at the positive position is also subject to an active transportation within the cell when the flow is switched on, the behaviour of the respective positions on flow stop is taken into account in order to evaluate the sensor signal. The signal increases at the flow stop in the case of a positive signal response. The reason for this lies in the increasing concentration of p-aminophenol at the position occupied by the enzyme, which is not removed through the flow. At the same time, the developing p-aminophenol is not transported to the adjacent negative position, thereby resulting in a disruption to the concentration and also to the measurable voltage signal when the flow is stopped.
This method has proven to be reliable in measuring blood samples, since no incorrect-positive measurement results were achieved, in other words, a positive blood sample was always present in the event of a positive sensor signal on flow stop.
Exemplary embodiments being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the present invention, and all such modifications as would be obvious to one skilled in the art are intended to be included within the scope of the following claims.
| Number | Date | Country | Kind |
|---|---|---|---|
| 10 2004 005 711.7 | Feb 2004 | DE | national |
